Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

Fig. 2

The PFS of patients treated with everolimus combined with endocrine therapy stratified by drugs that were previously used or not. A total of 120 patients received everolimus; 39 patients received a drug that was used in previous treatments (blue), and 81 patients received drugs that were not previously used (red). PFS, progression-free survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us